Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 6:41 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 7,857 matching trials from the live ClinicalTrials.gov search.
Filters: Minneapolis, Minnesota Clear all
Completed Phase 3 Interventional

Telehealth Nursing Intervention for Children With Complex Health Care Needs (CCHCN)

NCT01328353
View directory record Official record
Conditions
Unplanned Use of Health Care Services
Interventions
telehealth plus aprn triage
Other
Lead sponsor
University of Minnesota
Other
Eligibility
2 Years to 15 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Nov 2, 2026, 6:41 PM EST
Completed Phase 2 Interventional Results available

Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation

NCT04110145
View directory record Official record
Conditions
Functional Constipation
Interventions
Linaclotide, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
2 Years to 5 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
18
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Nov 2, 2026, 6:41 PM EST
Completed Phase 2 Interventional Results available

Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer

NCT01439945
View directory record Official record
Conditions
Breast Cancer, Cancer Survivor, Hot Flashes
Interventions
magnesium oxide, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
283
States / cities
Fairbanks, Alaska • Scottsdale, Arizona • Aurora, Colorado + 192 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Nov 2, 2026, 6:41 PM EST
Recruiting No phase listed Observational

TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients

NCT04098445
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplant (HSCT), Diffuse Alveolar Hemorrhage, Thrombotic Microangiopathies, Interstitial Pneumonitis, Bronchiolitis Obliterans
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 24 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2033
U.S. locations
9
States / cities
San Francisco, California • Aurora, Colorado • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Nov 2, 2026, 6:41 PM EST
Completed Phase 4 Interventional Results available

Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF)

NCT02677701
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
azithromycin, placebo (for azithromycin), inhaled tobramycin
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
12 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
39
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Nov 2, 2026, 6:41 PM EST
Completed No phase listed Observational

Detecting SARS-CoV-2 in Tears

NCT04526769
View directory record Official record
Conditions
COVID, COVID-19, Corona Virus Infection, SARS-CoV-2
Interventions
Tear Collection
Diagnostic Test
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Nov 2, 2026, 6:41 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Vascular Effects of Attention Deficit Hyperactivity Disorder (ADHD) Medications in Youth

NCT01107301
View directory record Official record
Conditions
ADHD
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
6 Years to 18 Years
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 5, 2014 · Synced Nov 2, 2026, 6:41 PM EST
Terminated No phase listed Observational

Comparison of "Wet Suction" Technique to Contemporary "Dry Suction" Technique Using a 22 Gauge Needle for EUS FNA

NCT01720745
View directory record Official record
Conditions
Cancer, Infection, Inflammation, Tumor, Sarcoid, Lymphadenopathy, Lymphoma
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Minneapolis, Minnesota • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Nov 2, 2026, 6:41 PM EST
Recruiting No phase listed Observational

A Long-term Follow-up Study in Patients Who Received BEAM-101

NCT07373639
View directory record Official record
Conditions
Hemoglobinopathy, Sickle Cell Disease
Interventions
Long-Term Follow-up Study of patients who received BEAM-101
Drug
Lead sponsor
Beam Therapeutics Inc.
Industry
Eligibility
14 Years to 37 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2043
U.S. locations
17
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Nov 2, 2026, 6:41 PM EST
Completed Not applicable Interventional Results available

An Integrated Program for the Treatment of First Episode of Psychosis

NCT01321177
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Brief Psychotic Disorder, Psychotic Disorder NOS
Interventions
Integrated Treatment, Community Care
Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 40 Years
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
33
States / cities
San Fernando, California • Santa Clarita, California • Denver, Colorado + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Nov 2, 2026, 6:41 PM EST
Completed Phase 1Phase 2 Interventional

Allogeneic ABCB5-positive Stem Cells for Treatment of Epidermolysis Bullosa

NCT03529877
View directory record Official record
Conditions
Recessive Dystrophic Epidermolysis Bullosa
Interventions
allo-APZ2-EB
Biological
Lead sponsor
RHEACELL GmbH & Co. KG
Industry
Eligibility
0 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 7, 2022 · Synced Nov 2, 2026, 6:41 PM EST
Completed Not applicable Interventional

Project 1, Study 1: Investigating the Impact of Nicotine Using Spectrum Cigarettes

NCT01681875
View directory record Official record
Conditions
Tobacco Dependence
Interventions
very low nicotine content cigarettes
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
839 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
9
States / cities
San Francisco, California • Tampa, Florida • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Nov 2, 2026, 6:41 PM EST
Terminated Phase 2 Interventional Results available

A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)

NCT02387957
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Fovista®, bevacizumab, ranibizumab, aflibercept
Drug
Lead sponsor
Ophthotech Corporation
Industry
Eligibility
50 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
24
States / cities
Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Nov 2, 2026, 6:41 PM EST
Completed Phase 2 Interventional

Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer

NCT00100945
View directory record Official record
Conditions
Esophageal Cancer
Interventions
gefitinib
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
119
States / cities
Mobile, Alabama • Jacksonville, Florida • Aurora, Illinois + 77 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Nov 2, 2026, 6:41 PM EST
Completed Phase 3 Interventional Results available

A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma

NCT06261957
View directory record Official record
Conditions
Asthma
Interventions
Salbutamol HFA-134a, Salbutamol HFA-152a
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
38
States / cities
North Hollywood, California • San Mateo, California • Aventura, Florida + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 2, 2026, 6:41 PM EST
Terminated Phase 3 Interventional Results available

TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy

NCT02322281
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Rociletinib, Pemetrexed or gemcitabine or paclitaxel or docetaxel
Drug
Lead sponsor
Clovis Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
31
States / cities
Bakersfield, California • Duarte, California • Fullerton, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Nov 2, 2026, 6:41 PM EST
Completed Phase 1 Interventional

Repetitive Transcranial Magnetic Stimulation (rTMS) to Promote Hand Recovery in Stroke

NCT00913211
View directory record Official record
Conditions
Stroke
Interventions
rTMS, Motor learning training, rTMS and Tracking, Sham rTMS
Device · Procedure
Lead sponsor
University of Minnesota
Other
Eligibility
21 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 31, 2011 · Synced Nov 2, 2026, 6:41 PM EST
Terminated Phase 2 Interventional Results available

Study of Antithymocyte Globulin for Treatment of New-onset T1DM

NCT00515099
View directory record Official record
Conditions
New-onset Type 1 Diabetes Mellitus
Interventions
Antithymocyte globulin, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 35 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
9
States / cities
Los Angeles, California • Oakland, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Nov 2, 2026, 6:41 PM EST
Recruiting Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

NCT06544499
View directory record Official record
Conditions
Primary Immune Thrombocytopenia (ITP)
Interventions
Efgartigimod IV, Placebo IV
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
18
States / cities
Phoenix, Arizona • Los Angeles, California • Oceanside, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Nov 2, 2026, 6:41 PM EST
Not listed Not applicable Interventional

Caisson Transcatheter Mitral Valve Replacement (TMVR) System Early Feasibility Study

NCT02768402
View directory record Official record
Conditions
Mitral Valve Regurgitation
Interventions
Caisson TMVR System
Device
Lead sponsor
Caisson Interventional LLC
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
13
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Delray Beach, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Nov 2, 2026, 6:41 PM EST
Completed Phase 1Phase 2 Interventional Results available

Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML)

NCT03303339
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Onvansertib, Cytarabine, Decitabine
Drug
Lead sponsor
Cardiff Oncology
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
9
States / cities
Los Angeles, California • New Haven, Connecticut • Westwood, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Nov 2, 2026, 6:41 PM EST
Completed Phase 2 Interventional Results available

Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure

NCT01982292
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
RLX030 (serelaxin), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
9
States / cities
Anaheim, California • Colorado Springs, Colorado • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2016 · Synced Nov 2, 2026, 6:41 PM EST
Terminated Phase 1Phase 2 Interventional

Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma

NCT02102022
View directory record Official record
Conditions
Advanced Gastrointestinal (GI) Malignancies, Hepatocellular Carcinoma, Gastric Cancer, Colorectal Cancer
Interventions
ADI-PEG 20 plus modified FOLFOX6
Drug
Lead sponsor
Polaris Group
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
10
States / cities
San Francisco, California • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Nov 2, 2026, 6:41 PM EST
Completed Phase 1 Interventional Results available

A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML

NCT01861002
View directory record Official record
Conditions
Lymphoblastic Leukemia, Acute, Childhood, Myelogenous Leukemia, Acute, Childhood
Interventions
Azacytidine, Fludarabine, Cytarabine, Intrathecal (IT) Cytarabine, Intrathecal Methotrexate (IT MTX)
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
19
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Nov 2, 2026, 6:41 PM EST